Literature DB >> 6695149

Serum thymidine kinase in vitamin B12 deficiency.

H Hagberg, S Gronowitz, A Killander, C Källander.   

Abstract

In DNA synthesis deoxythymidine kinase (TK) catalyses the conversion of deoxythymidine to deoxythymidine monophosphate (dTMP) via the 'salvage pathway'. Serum deoxythymidine kinase (S-TK) was measured in this study in 75 patients with vitamin B12 deficiency by a new, very sensitive method, using 125I-deoxyuridine as substrate. Elevated S-TK levels were found in those patients who had developed haemolysis and anaemia and the more advanced the disease the higher the S-TK value. Thus there was a highly significant correlation between S-TK, haemoglobin level and lactic dehydrogenase activity. These findings are consistent with the theory that elevated levels of S-TK are due to release from unstable proliferating tissue.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695149     DOI: 10.1111/j.1600-0609.1984.tb00675.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  10 in total

Review 1.  Thymidine kinase: a tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications.

Authors:  M Hallek; L Wanders; S Strohmeyer; B Emmerich
Journal:  Ann Hematol       Date:  1992-07       Impact factor: 3.673

2.  Neuron specific enolase (NSE) and thymidine kinase (TK) as markers in biological fluids of brain tumor patients.

Authors:  A Boiardi; L Munari; A Silvani; C L Solero; E Bombardieri
Journal:  Ital J Neurol Sci       Date:  1990-08

3.  Molecular forms in human serum of enzymes synthesizing DNA precursors and DNA.

Authors:  A R Karlström; M Neumüller; J S Gronowitz; C F Källander
Journal:  Mol Cell Biochem       Date:  1990-01-18       Impact factor: 3.396

4.  Serum thymidine kinase, a possible marker for monitoring the effect of bone marrow transplant treatment in early recovery phase.

Authors:  M Suehiro; M Fukuchi; M Kohsaki; Y Takemoto; A Kanamaru; E Kakishita
Journal:  Ann Nucl Med       Date:  1992-05       Impact factor: 2.668

5.  Activity of serum thymidine kinase in non-Hodgkin lymphoma: relationship to other prognostic factors.

Authors:  M Hallek; B Emmerich; S Strohmeyer; R Busch; A Reichle; R Senekowitsch
Journal:  Klin Wochenschr       Date:  1988-08-15

6.  Deoxythymidine-kinase in cerebrospinal fluid: a new potential "marker" for brain tumours.

Authors:  J S Gronowitz; C F Källander; H Hagberg; L Persson
Journal:  Acta Neurochir (Wien)       Date:  1984       Impact factor: 2.216

7.  Serum thymidine kinase in acute leukaemia.

Authors:  H Hagberg; S Gronowitz; A Killander; C Källander; B Simonsson; C Sundström; G Oberg
Journal:  Br J Cancer       Date:  1984-04       Impact factor: 7.640

8.  Serum Thymidine Kinase 1, Canine-C-Reactive Protein, Haptoglobin, and Vitamin D Concentrations in Dogs with Immune-Mediated Hemolytic Anemia, Thrombocytopenia, and Polyarthropathy.

Authors:  M Grobman; H Outi; H Rindt; C Reinero
Journal:  J Vet Intern Med       Date:  2017-08-14       Impact factor: 3.333

9.  Deoxythymidine kinase in the tumour cells and serum of patients with non-Hodgkin lymphomas.

Authors:  S Rehn; J S Gronowitz; C Källander; C Sundström; B Glimelius
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

10.  Serum thymidine kinase activity: analytical performance, age-related reference ranges and validation in chronic lymphocytic leukemia.

Authors:  Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.